Trials / Terminated
TerminatedNCT00100152
A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)
A Phase I Study of a Gamma Secretase Inhibitor for Adult and Pediatric Patients With Relapsed or Refractory Acute T-Cell Lymphoblastic Leukemia and Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (planned)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 12 Months
- Healthy volunteers
- Not accepted
Summary
A Notch signalling pathway inhibitor study in pediatric and adult patients with relapsed (worsening) or refractory (not responding to treatment) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL).
Conditions
- Leukemia, Lymphoblastic, Acute, T-cell
- Myelogenous Leukemia
- Chronic Lymphocytic Leukemia
- Myelodysplastic Syndromes
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0752, (Notch Inhibitor) |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2006-09-01
- Completion
- 2006-10-01
- First posted
- 2004-12-24
- Last updated
- 2015-05-27
Source: ClinicalTrials.gov record NCT00100152. Inclusion in this directory is not an endorsement.